Introducing ICAM1 as a possible drug target in treatment of eosinophilic esophagitis
Alireza Omidi Farzin, Nikoo Hossein-Khannazer, Babak Arjmand, Nastaran Asri, Zahra Razzaghi, Mostafa Rezaei-Tavirani, Mohammad Javad Ehsani Ardakani, Hamid Mohaghegh-Shalmani · 2025
Read Introducing ICAM1 as a possible drug target in treatment of eosinophilic esophagitis by Alireza Omidi Farzin, Nikoo Hossein-Khannazer, Babak Arjmand, Nastaran Asri, Zahra Razzaghi, Mostafa Rezaei-Tavirani, Mohammad Javad Ehsani Ardakani, Hamid Mohaghegh-Shalmani (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-13081418.txt.
Description
Alireza Omidi Farzin and co-authors mine in 2025 gene data for the drivers of a chronic food pipe disease. Eosinophilic esophagitis fills the gullet lining with allergy-linked white cells and disrupts swallowing. Several interleukin signals were already known to run high, but the control web behind them was fuzzy.
From a public gene database the team pulled the genes that differ most between patients and healthy people, then mapped how their proteins interact. Nineteen genes stood out as hubs. One surface protein, ICAM1, sat under the control of top hubs and was flagged as a drug target. The authors suggest tuning it could slow the disease.
Catalog record
| CREATOR | Alireza Omidi Farzin, Nikoo Hossein-Khannazer, Babak Arjmand, Nastaran Asri, Zahra Razzaghi, Mostafa Rezaei-Tavirani, Mohammad Javad Ehsani Ardakani, Hamid Mohaghegh-Shalmani |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 16 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |